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The central tenet of clinical research in humans is that par-ticipation is informed and voluntary. Participation is considered to be in-formed only when there are properly scrutinized protocols and when par-
ticipants are fully informed of the known risks, discomforts, and inconveniences 
related to their involvement.1 Across the many types of clinical investigation, the 
randomized, controlled trial is the key scientific tool used to measure the efficacy 
and adverse effects of a diagnostic or therapeutic approach.2 Randomization, the 
critical element used to reduce bias, not uncommonly creates ethical quandaries, 
since the treating physician and the patient, by agreeing to participate in the trial, 
forgo their choice of the intervention being tested, leaving this to chance.3 For 
those designing the trial, making the decision as to whether the comparator treat-
ment should be an inert substance — that is, a placebo — or an active treatment 
can be difficult. For those making the decision as to whether to participate, it is 
important that they fully understand the medical question being explored and the 
role they will play in helping to obtain an answer.
Clinical trials do not occur in a vacuum. Before a major clinical-outcome trial 
is started, there is often substantial information available about the intervention 
from smaller, hypothesis-generating trials that are usually intended to examine 
the effects of the intervention on less definitive outcomes, such as a biomarker or 
a surrogate end point that is believed to correlate with changes in clinical events. 
In some cases observational data may be available, and in other instances previous 
clinical-outcome trials have established the effectiveness of an agent but have done 
so in a different patient population. Sometimes this existing information engen-
ders divergent and even polarized opinions. In that case, a randomized trial of 
high quality should be welcomed by all parties as the best means to resolve the 
controversy. Even so, strong preferences may undermine support for the random-
ization process, affecting the veracity of the trial by injecting bias into the selec-
tion of patients. In other instances, a solid consensus coalesces around what are 
perceived to be the best existing data. When the intervention in question is already 
generally part of clinical practice, many health professionals find comfort in its 
use and view a randomized trial as unnecessary or even unethical, since some 
patients would not receive the therapy that they would have received in the absence 
of the trial. In this article, we use examples from cardiovascular medicine to dis-
cuss the effects of the existing and evolving information on trial design with re-
gard to the choice of placebo or active comparator agents and to the definition of 
the population of patients in the trial.
Regardless of whether the prestudy perception is one of clinical equipoise or 
involves a range of uncertainty, if a randomized trial is to be initiated and con-
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ducted, the fundamental question it addresses 
must be worthy of the major collective efforts 
required of patients, investigators, and spon-
sors.4 It is important to note that regardless of 
the level of confidence in the prestudy informa-
tion, a randomized, controlled trial remains a 
scientific experiment. Properly worded consent 
forms should not lead a participant to expect any 
unproven benefits.
Notwithstanding the careful planning of the 
experts who design the trial, the scrutiny of 
regulatory agencies, and the commitment of re-
sources from sponsors to demonstrate proposed 
theoretical benefits, many researchers conclude 
that the intervention they had hoped would offer 
a diagnostic or therapeutic advance is no better 
than the existing options.5,6 The effectiveness of 
an intervention is best evaluated in randomized 
trials in which well-defined clinical events are 
the primary outcome.
In the absence of clinical-outcome data that 
provide definitive direction, surrogate measures 
are often used to direct therapeutic decisions. 
Consistent linkage from reliable observational 
data between a commonly used biologic measure-
ment and prognosis can understandably lead to 
a perceived association that changes in that bio-
marker can be reasonably assumed to cause direc-
tionally similar alterations in clinical outcomes. 
For many of these biologic measures, such as 
levels of high-density lipoprotein cholesterol or 
hemoglobin, the density of ventricular arrhyth-
mias, and left ventricular ejection fraction, multi-
ple observational studies are available that show 
such quantitative associations with cardiovascular 
risk.7 The finding of a quantitative relationship 
between the degree of deviation of the measured 
marker from normality and adverse outcomes 
has on occasion fostered the reasonable expecta-
tion for both drug discovery and clinical practice 
that therapies that restore the abnormal mea-
surement toward normal would have a favorable 
outcome.
In cardiovascular medicine, this comfort zone 
was shattered by the results of the Cardiac Ar-
rhythmia Suppression Trial, which showed that 
despite the clear association between the de-
gree of ventricular ectopy and risk of death, anti-
arrhythmic therapy, which was effective in sup-
pressing ventricular premature beats, increased 
rather than decreased mortality.8 Before this 
placebo-controlled trial was conducted, a major 
emphasis was placed on detecting patients with 
asymptomatic ventricular arrhythmias in order 
to initiate antiarrhythmic agents that would pro-
vide the assumed benefits. The totally unexpected 
result — that treating these abnormal rhythms 
with antiarrhythmic agents was associated with 
increased mortality — painfully disclosed the 
false sense of security of what was then a widely 
adopted clinical practice. The prompt translation 
of these findings into reductions in the use of 
these unsafe therapies improved public health 
and created additional uncertainties. These sur-
prising findings also raised questions about other 
cardiovascular therapies whose use had became 
widespread after regulatory evaluations were 
satisfied, predominantly on the basis of altera-
tions of surrogate measures rather than clinical 
events.
E a r ly Data on Bl o od Pr essur e 
a nd Ou t comes
Our story is about the treatment of hypertension 
and the finding in multiple trials that the normal-
ization of blood pressure has been consistently 
accompanied by beneficial clinical outcomes 
(Fig. 1). Elevations in systemic arterial pressure 
were identified in early pioneering epidemio-
logic studies (e.g., the Framingham Heart Study 
and the Multiple Risk Factor Intervention Trial 
[MRFIT]) as being tightly coupled to a height-
ened risk of illness and death from cardiovascu-
lar disease.9,10 A historical review of some of the 
predominantly government-sponsored random-
ized trials that were designed to ascertain wheth-
er and when long-term antihypertensive therapy 
lowers these risks illustrates several of the ethi-
cal issues that influence the comparators and 
the patient populations chosen for study as new 
information is generated.
One of the early randomized, placebo-con-
trolled, clinical-outcome trials in cardiovascular 
medicine, commencing in 1963, was conducted 
by the Veterans Administration (VA) Cooperative 
Study Group on Antihypertensive Agents. In its 
trial involving 143 men whose diastolic blood 
pressure was between 115 and 129 mm Hg, the 
group found that the use of a combination of 
three antihypertensive agents resulted in fewer 
cardiovascular events than the use of placebo.11 
Since the risks and the potential benefits of us-
ing pharmacologic agents to reduce blood pres-
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sure were unknown, placebo was unquestion-
ably the correct comparator. The same group 
concurrently conducted another trial of 380 men 
whose diastolic pressures were between 90 and 
114 mm Hg.12 The lower diastolic pressure of the 
participants in this trial made placebo the appro-
priate control for this previously unstudied popu-
lation. The combination of the participants’ lower 
diastolic pressure and the fact that this popula-
tion had not been studied previously also made 
placebo the appropriate control in this trial. The 
findings of each of these placebo-controlled 
trials, which showed that the adverse cardiovas-
cular consequences of elevated blood pressure 
could be reduced by the administration of anti-
hypertensive medications, are now considered to 
be foundational evidence for the concept of pre-
ventive medicine. However, at the time, the clini-
cal importance of treating an asymptomatic per-
son with the available therapies for lowering 
blood pressure was not readily accepted by the 
medical community.
R eco gni tion of the Da nger s  
of H y pertension
The National High Blood Pressure Education Pro-
gram was established in 1972 by philanthropist 
Mary Lasker and then-Secretary of Health, Edu-
cation, and Welfare Elliot Richardson with the 
objective of alerting physicians and the public to 
the risks of hypertension.13 This government-
funded educational program used phrases such 
as “the silent killer” to heighten awareness of 
Figure 1. Trials Influencing Blood-Pressure Thresholds at Which Antihypertensive Medications Should Be Used.
ACCORD denotes Action to Control Cardiovascular Risk in Diabetics, ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial, Australian Trial the Australian Therapeutic Trial, ESH–ESC the European Society of Hypertension–European Society 
of Cardiology Guidelines, HDFP Hypertension Detection and Follow-up Program, HOPE Heart Outcomes Prevention Evaluation, HOT 
Hypertension Optimal Treatment, HYVET Hypertension in the Very Elderly Trial, JNC Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure, MRC Medical Research Council, SHEP Systolic Hypertension in the Elderly Program, 
SPRINT Systolic Blood Pressure Intervention Trial, STOP Swedish Trial in Old Patients with Hypertension, Syst-Eur Systolic Hypertension in 
Europe, and VA Veterans Administration Cooperative Study Group. The asterisk that follows JNC 8 denotes findings that appear as they 
were submitted by the appointed panel members, without official endorsements.
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the dangers of elevated blood pressure and to 
encourage the use of antihypertensive therapy 
in patients with hypertension. The reluctance of 
the medical community to accept the findings 
of the two VA trials was reflected in the design of 
subsequent major trials focused on hypertension.
The investigators conducting the Hyperten-
sion Detection and Follow-up Program (HDFP) 
that was sponsored by National Institutes of 
Health designed their trial to determine whether 
improved blood-pressure control could prolong 
survival. The trial included nearly 11,000 people, 
and enrollment began in 1974. Given that study 
entry required a diastolic blood pressure of at 
least 90 mm Hg (with more than 1000 partici-
pants having a diastolic pressure of more than 
115 mm Hg at study entry), the HDFP was in 
some respects an effort to confirm the results of 
the VA trials while also expanding the population 
covered to include women and younger people. 
Despite these population differences, the design-
ers of the HDFP “agreed that the results of the 
Veterans trials made it inappropriate to use pla-
cebo controls.”14 This clear statement and early 
shift from placebo to an active comparator indi-
cated that the investigators believed that it was 
unethical to withhold the opportunity for anti-
hypertensive therapy from participants during a 
long-term clinical trial. However, the tension be-
tween clinical investigators and community prac-
titioners with regard to the acceptance of the 
existing data was reflected in the trial design 
and the differential use of antihypertensive drugs 
between groups.
In this 5-year HDFP, a total of 10,940 volun-
teers (46% of whom were women) were randomly 
assigned to receive either stepped care (SC), in 
which antihypertensive therapy was provided at 
specialized sites and doses increased to achieve 
and maintain specific blood-pressure goals, or 
referred care (RC), in which participants were 
referred to their usual sources of care. The de-
sign was based on an inherent assumption that 
despite the absence of placebo, the ambivalence 
of the medical community toward antihyperten-
sive drugs would result in fewer prescriptions in 
the RC group than in the SC group. Although a 
considerable number of patients in each group 
remained untreated, the percentage was more 
than twice as high in the RC group at year 2, 
with 18.5% of the SC group and 41.7% of the RC 
group remaining untreated. The goal of attain-
ing a diastolic pressure of less than 90 mm Hg 
was achieved in 56.7% of the patients in the SC 
group and in only 33.7% of the patients in the 
RC group. Even this difference in the intensity of 
blood-pressure treatment was associated with a 
statistically and clinically significant difference in 
mortality, which was 17% lower in the SC group 
than in the RC group.14
The response of the international medical 
community to the results of the two relatively 
small initial VA studies was even more restrained 
than that in the United States. Near the time at 
which the HDFP was being conducted in the 
United States, three trials related to hypertension 
control were being performed outside the United 
States. In each of these trials, placebo was select-
ed as the comparator (Table 1). Entry into the 
European Working Party Trial16 and the Medi-
cal Research Council Trial (conducted in the Unit-
ed Kingdom)17 required a diastolic pressure of 
90 mm Hg or higher, and entry into the Austra-
lian Therapeutic Trial15 required a diastolic pres-
sure of 95 mm Hg or higher. The use of placebo 
in all three trials, which commenced in the 
1970s, was a clear indication that the research-
ers’ level of uncertainty with regard to the need 
to treat people with this level of blood pressure 
was higher than it was for the U.S. investigators 
in the HDFP. Nonetheless, hypertension knows 
no borders, and all three trials showed that fewer 
cardiovascular events occurred among patients 
with better blood-pressure control. With these 
findings, the importance of lowering blood pres-
sure was solidified (Table 1).
The design of the Hypertension Optimal Treat-
ment (HOT) trial, conducted in the mid-1990s, 
showed that the international community of re-
searchers who were investigating hypertension 
had accepted the proposition that in patients 
with elevated diastolic blood pressure, the re-
duction of that pressure with antihypertensive 
drugs improved cardiovascular outcomes.21 In the 
HOT trial, the diastolic pressure of participants 
was between 100 and 115 mm Hg, and all re-
ceived active antihypertensive therapy. Participants 
were randomly assigned to one of three groups 
in which the targeted diastolic blood pressures 
were less than 90, less than or equal to 85, or less 
than or equal to 80 mm Hg. Although no signifi-
cant differences in the rates of major cardiovas-
cular events were observed across the three levels 
of treatment intensity, this trial, which included 
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Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
18,790 participants, made a clear statement that 
elevated diastolic pressure should be lowered to 
at least 90 mm Hg.
Shif t t o S ys t olic Pr essur e
The Systolic Hypertension in the Elderly Pro-
gram (SHEP), which was conducted from 1985 
through 1991, involved 4736 patients, was one 
of the first trials to address the use of systolic 
blood pressure as a guide for initiating anti-
hypertensive treatment. In order to participate, 
a patient had to have a systolic blood pressure 
between 160 and 219 mm Hg and a diastolic 
pressure of less than 90 mm Hg (average blood 
pressure, 170/77 mm Hg).18 Although these levels 
of systolic pressure are very high by today’s stan-
dards, the benefits and risks of antihypertensive 
therapy in this generally older population were 
unknown at the time the trial was conducted. 
Although placebo was used as the control, the 
trial included an “escape” clause that allowed for 
the initiation of open-label therapy for patients 
whose systolic blood pressure was higher than 
220 mm Hg. At year 2, a total of 6.7% of the 
active-treatment group and 70.9% of the placebo 
group were not being treated, and the between-
group difference in systolic pressure was approxi-
mately 13 mm Hg. The active-treatment group 
had a rate of stroke that was 36% lower than 
that in the placebo group and a composite rate 
of nonfatal myocardial infarction, death from 
coronary heart disease, or heart failure that was 
33% lower.
The European Working Party on High Blood 
Pressure in the Elderly investigated isolated sys-
tolic hypertension in the Systolic Hypertension in 
Europe (Syst-Eur) trial.20 The entry criterion for 
this randomized, placebo-controlled trial was a 
systolic blood pressure of 160 to 219 mm Hg, 
with a diastolic pressure of less than 95 mm Hg. 
The Syst-Eur trial, which was conducted from 
1989 through 1997, was continued after the re-
sults of SHEP were known “because of remain-
ing uncertainties about the treatment of isolated 
systolic hypertension in the elderly.”20 The trial 
was stopped after an interim analysis showed that 
the incidence of the primary end point (stroke) 
was 42% lower in the active-treatment group 
than in the placebo group (P = 0.003). The inci-
dence of heart failure and myocardial infarction 
was 25% lower in the active-treatment group.T
ri
al
El
ig
ib
ili
ty
C
om
pa
ra
to
rs
B
lo
od
 P
re
ss
ur
e 
at
 I
nc
lu
si
on
O
ut
co
m
e
Pl
ac
eb
o 
U
se
d
Is
su
es
 R
eg
ar
di
ng
 
U
se
 o
f P
la
ce
bo
m
m
 H
g
SP
R
IN
T 
(2
01
5)
26
  
D
ur
at
io
n:
 2
01
0–
20
15
 
Pa
rt
ic
ip
an
ts
: 9
36
1
Sy
st
ol
ic
 p
re
ss
ur
e 
 
13
0–
18
0 
m
m
 H
g,
  
ri
sk
 fa
ct
or
s 
fo
r 
ca
rd
io
-
va
sc
ul
ar
 d
is
ea
se
 (
pe
r-
so
ns
 p
ar
tic
ip
at
in
g 
in
 
A
C
C
O
R
D
 o
r 
hi
st
or
y 
of
 
st
ro
ke
 e
xc
lu
de
d;
 c
an
 b
e 
ta
ki
ng
 a
nt
ih
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n)
In
te
ns
iv
e 
co
nt
ro
l (
ta
rg
et
 
<1
20
 m
m
 H
g)
 o
r 
st
an
da
rd
 c
on
tr
ol
 (
ta
r-
ge
t <
14
0 
m
m
 H
g)
In
te
ns
iv
e 
co
nt
ro
l: 
14
0/
78
 
St
an
da
rd
 c
on
tr
ol
: 1
40
/7
8
D
ec
re
as
e 
of
 2
5%
 fo
r 
pr
im
ar
y 
ou
tc
om
e 
of
 d
ea
th
 fr
om
 
ca
rd
io
va
sc
ul
ar
 d
is
ea
se
, 
ac
ut
e 
co
ro
na
ry
 s
yn
-
dr
om
e,
 m
yo
ca
rd
ia
l i
n-
fa
rc
tio
n,
 o
r 
st
ro
ke
, o
r 
he
ar
t f
ai
lu
re
 (
P<
0.
00
1)
; 
de
cr
ea
se
 o
f 2
7%
 in
 
 m
or
ta
lit
y 
(P
 =
 0
.0
03
)
N
o
Li
ke
 A
C
C
O
R
D
, t
ri
al
 a
dd
re
ss
ed
 
 ef
fe
ct
s 
of
 tr
ea
tm
en
t i
nt
en
si
ty
 
ra
th
er
 th
an
 tr
ea
tm
en
t i
ni
tia
-
tio
n 
bu
t i
n 
di
ffe
re
nt
 p
at
ie
nt
 
po
pu
la
tio
n
H
O
PE
–3
 (
20
16
)2
7   
D
ur
at
io
n:
 2
00
7–
20
15
 
Pa
rt
ic
ip
an
ts
: 1
2,
70
5
N
o 
kn
ow
n 
ca
rd
io
va
sc
ul
ar
 
di
se
as
e,
 b
ut
 a
t l
ea
st
 o
ne
 
ris
k 
fa
ct
or
 fo
r c
ar
di
ov
as
-
cu
la
r d
is
ea
se
; n
ee
d 
fo
r 
in
iti
at
io
n 
of
 h
yp
er
te
ns
iv
e 
tr
ea
tm
en
t d
et
er
m
in
ed
 o
n 
ba
si
s 
of
 lo
ca
l s
ta
nd
ar
ds
C
an
de
sa
rt
an
 p
lu
s 
hy
dr
o-
ch
lo
ro
th
ia
zi
de
 v
s.
 
 pl
ac
eb
o,
 w
ith
 2
-b
y-
2 
fa
ct
or
ia
l d
es
ig
n 
of
 
st
at
in
 v
s.
 p
la
ce
bo
Tr
ea
tm
en
t: 
13
8/
82
 
Pl
ac
eb
o:
 1
38
/8
2
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 
ra
te
s 
of
 c
ar
di
ov
as
cu
la
r 
de
at
h,
 n
on
fa
ta
l m
yo
ca
r-
di
al
 in
fa
rc
tio
n,
 o
r 
st
ro
ke
Ye
s
A
dd
re
ss
ed
 lo
w
er
 e
nd
 o
f b
lo
od
-
pr
es
su
re
 s
pe
ct
ru
m
 a
nd
 r
is
k 
sp
ec
tr
um
* 
 A
C
C
O
R
D
 d
en
ot
es
 A
ct
io
n 
to
 C
on
tr
ol
 C
ar
di
ov
as
cu
la
r 
R
is
k 
in
 D
ia
be
tic
s,
 A
C
E 
an
gi
ot
en
si
n-
co
nv
er
tin
g–
en
zy
m
e,
 A
LL
H
A
T 
A
nt
ih
yp
er
te
ns
iv
e 
an
d 
Li
pi
d-
Lo
w
er
in
g 
Tr
ea
tm
en
t 
to
 P
re
ve
nt
 H
ea
rt
 
A
tt
ac
k 
Tr
ia
l, 
H
D
FP
 H
yp
er
te
ns
io
n 
D
et
ec
tio
n 
an
d 
Fo
llo
w
-u
p 
Pr
og
ra
m
, H
O
PE
 H
ea
rt
 O
ut
co
m
es
 P
re
ve
nt
io
n 
Ev
al
ua
tio
n,
 H
O
T 
H
yp
er
te
ns
io
n 
O
pt
im
al
 T
re
at
m
en
t, 
H
YV
ET
 H
yp
er
te
ns
io
n 
in
 t
he
 
V
er
y 
El
de
rl
y 
Tr
ia
l, 
M
R
C
 M
ed
ic
al
 R
es
ea
rc
h 
C
ou
nc
il,
 S
H
EP
 S
ys
to
lic
 H
yp
er
te
ns
io
n 
in
 t
he
 E
ld
er
ly
 P
ro
gr
am
, S
PR
IN
T 
Sy
st
ol
ic
 B
lo
od
 P
re
ss
ur
e 
In
te
rv
en
tio
n 
Tr
ia
l, 
ST
O
P 
Sw
ed
is
h 
Tr
ia
l i
n 
O
ld
 
Pa
tie
nt
s 
w
ith
 H
yp
er
te
ns
io
n,
 S
ys
t-
Eu
r 
Sy
st
ol
ic
 H
yp
er
te
ns
io
n 
in
 E
ur
op
e,
 a
nd
 V
A
 G
ro
up
 V
et
er
an
s 
A
dm
in
is
tr
at
io
n 
C
oo
pe
ra
tiv
e 
St
ud
y 
G
ro
up
.
Ta
bl
e 
1.
 (C
on
tin
ue
d.
)
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on January 27, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;18 nejm.org November 3, 2016 1763
Clinical Trials Series
The Swedish Trial in Old Patients with Hyper-
tension (STOP-Hypertension) was also conducted 
during this period (1985–1991) and also used 
placebo rather than active treatment in the 
comparator group.19 On entry into the trial, par-
ticipants had to have a diastolic blood pressure 
between 105 and 120 mm Hg (irrespective of 
systolic pressure) or both a diastolic pressure 
of at least 90 mm Hg and a systolic pressure be-
tween 180 and 230 mm Hg. The diastolic criteria 
overlapped with those for participation in previous 
trials, as the investigators acknowledged in their 
stated objective: “to confirm the value of antihy-
pertensive treatment in people age 70–74 years 
and to expand the database up to the age of 84 
years.” The blood-pressure levels at year 2 of the 
study were 188/97 mm Hg in the placebo group 
and 166/87 mm Hg in the treatment group. The 
rate of cardiovascular death, myocardial infarc-
tion, or stroke was 38% lower in the active-
treatment group (Table 1).
These trials from the 1980s and early 1990s 
generated the data needed to develop a systolic 
blood-pressure target for the initiation of anti-
hypertensive therapy. The cumulative evidence 
provided the basis for the recommendations 
initially made in the 1993 report of the Joint 
National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pres-
sure (Fig. 1) to start long-term antihypertensive 
therapy at a systolic pressure of 140 mm Hg or 
higher or a diastolic pressure of 90 mm Hg or 
higher.
Emergence of E thic a l Issues  
a s  K now led ge Accumul ates
The ethical boundaries of finding sufficient un-
certainty for the use of placebo in patients with 
hypertension were probed more recently in the 
Hypertension in the Very Elderly Trial (HYVET), 
which was conducted from 2000 through 2007. 
In this major outcome trial, active antihyperten-
sive therapy was compared with placebo in pa-
tients 80 years of age or older who had a systolic 
pressure of 160 mm Hg or higher.24 The ratio-
nale was that minimal data on the effectiveness 
or safety of antihypertensive therapy were avail-
able in this population. Although the rate of the 
primary end point of stroke was not significantly 
lower than the rate with placebo, the 21% lower 
rate of death (P<0.02) in the active antihyperten-
sive-therapy group confirmed the importance of 
lowering blood pressure regardless of age and 
closed the chapter on the use of placebo in con-
trolled trials addressing this level of hyperten-
sion (Table 1).
In the Heart Outcomes Prevention Evalua-
tion (HOPE)–3 trial,27 the results of which were 
reported in spring 2016, the investigators used 
placebo as the comparator with active combi-
nation antihypertensive therapy to evaluate the 
risks and benefits of blood-pressure control in 
persons whom investigators believed did not 
have a clear current indication for the active 
therapies being evaluated. Participants could 
enter the trial after blood-pressure control was 
attained with lifestyle interventions or with drugs 
other than an angiotensin-receptor–blocker, an 
angiotensin-converting-enzyme inhibitor, or a 
thiazide diuretic. In effect, this design, which 
permitted some participants in the control group 
to receive antihypertensive therapy, was a hybrid 
between no treatment and add-on therapy, since 
at baseline 22% of patients were already receiv-
ing treatment intended to lower blood pressure. 
With the mean blood pressure at baseline at 
138/82 mm Hg, some participants had a blood-
pressure level that was above the existing treat-
ment targets and the targets being introduced at 
the time the trial started (Fig. 1).
The trial results were neutral, with no signifi-
cant difference reported between placebo and 
active therapy for the composite rate of cardio-
vascular events. However, in a subgroup analysis 
of the participants with the highest systolic 
pressure at trial entry (>143.5 mm Hg), those 
who received combination antihypertensive ther-
apy had fewer cardiovascular events than those 
receiving placebo. What made this modern pla-
cebo-controlled trial distinctive was the fact that 
it explored the lower limits at which antihyper-
tensive therapy should be provided by offering 
treatment to participants who were not consid-
ered to need either initiation of such treatment 
or any additional treatment — an understudied 
population with an annual risk of major cardio-
vascular events of approximately 1%. The trial 
also had a 2-by-2 factorial design in which a 
statin was provided for the purpose of preventing 
cardiovascular events without the use of lipid or 
blood-pressure targets or monitoring.
As the data on the benefits of antihyperten-
sive therapy have increased, ethical standards in 
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this field have continued to evolve.28 Generally, 
institutional review boards will permit only short-
term withholding (approximately 2 to 4 weeks) 
of antihypertensive medications (within a non-
severe blood-pressure range) to establish baseline 
blood pressure. Most current trials assessing 
the effects of lowering blood pressure compare 
the effects of a new therapy with those of an 
established comparator rather than placebo.23,28-31 
The comparisons between specific antihyperten-
sive agents are often made at doses that achieve 
similar degrees of blood-pressure control. Al-
though some large clinical-outcome trials that 
compare specific antihypertensive agents have 
been conducted to identify possible benefits of 
treatment other than that of lowering blood pres-
sure,23,29,31 for the most part reductions in the 
occurrence of major cardiovascular events are 
more closely related to the extent to which blood 
pressure is lowered than to the class of agent 
used.32 One of the largest trials in which active 
agents were used as comparators was the Anti-
hypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT) sponsored 
by the National Heart, Lung, and Blood Institute 
(NHLBI), in which a diuretic was compared with 
three other classes of antihypertensive drug.23 In 
this trial, which was conducted from 1994 through 
2002, the finding that the risk of the develop-
ment of heart failure was twice as high with 
doxazosin as it was with chlorthalidone provid-
ed the research community with an important 
lesson in humility.22
Be yond Pl acebo
The clinical-outcome trials involving hyperten-
sion that were conducted in the past decade ad-
dressed the level at which antihypertensive treat-
ment should be initiated and at what intensity; 
these trials did not use a placebo. Since the epi-
demiologic data relating blood pressure and car-
diovascular risk do not show a clear threshold 
(i.e., a level below which risk does not appear to 
diminish),9,10 there was a widely held belief that 
the use of antihypertensive drugs to bring blood 
pressure below the operational definition of 
hypertension would further improve prognosis. 
For patients with type 2 diabetes, this belief was 
supported by a subgroup analysis from the HOT 
trial that showed that among the 1501 patients 
in the trial who had diabetes, there was a grada-
tion in the observed rate of cardiovascular events 
across the three groups that had met the target 
diastolic pressure.21 This finding led to the rec-
ommendation of an even lower target blood 
pressure in these patients.28 However, it was ac-
knowledged that this target was based on sub-
group data.
There was sufficient uncertainty regarding the 
recommendation that one aspect of the NHLBI-
sponsored Action to Control Cardiovascular Risk 
in Diabetics (ACCORD) trial was specifically de-
signed to address this question.25 In ACCORD, an 
open-label trial that commenced in 2001, patients 
were randomly assigned to receive either inten-
sive antihypertensive therapy targeting systolic 
blood pressures of less than 120 mm Hg or 
standard therapy targeting systolic blood pres-
sures of less than 140 mm Hg. The group receiv-
ing standard treatment was to have at least the 
currently recommended level of blood-pressure 
control, and the focus was on between-group 
differences in blood-pressure levels, not on the 
specific antihypertensive agents used. The group 
receiving intensive treatment was in effect pro-
viding the unknown relative efficacy and safety 
data related to the use of a greater number of 
antihypertensive medications intended to lower 
blood pressure to levels not previously studied in 
major clinical-outcome trials.
Despite achieving an impressive average dif-
ference of 14 mm Hg in systolic pressure, the 
primary composite outcome of time to cardio-
vascular death, myocardial infarction, or stroke 
was not lower in the group receiving intensive 
therapy than in the group receiving standard 
therapy. The trial also showed that there was a 
downside to the strategy of striving for greater 
and greater reductions in blood pressure, since 
a higher number of serious adverse events (i.e., 
events that were life-threatening, caused perma-
nent disability, or necessitated hospitalization) 
that were attributed to antihypertensive medica-
tions were reported in the group receiving inten-
sive treatment. The results of the ACCORD trial 
did not align with expert consensus,34 which 
provided another lesson in humility from a well-
conducted outcome trial that improved practice 
and defied expert opinion.
The even more recent NHLBI-sponsored Sys-
tolic Blood Pressure Intervention Trial (SPRINT),26 
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the results of which were published in 2015, 
addressed the same question in a population with 
a high level of cardiovascular risk. However, in 
light of the neutral findings related to target 
blood pressures from the ACCORD trial and the 
Secondary Prevention of Small Subcortical Strokes 
trial,33 the SPRINT investigators excluded patients 
with diabetes or a history of stroke. Again, the 
design was a randomized, controlled trial in 
which patients used open-label antihypertensive 
agents to a target systolic pressure of either less 
than 120 or less than 140 mm Hg. Although in 
the ACCORD trial the group receiving the more 
intensive approach to lowering systolic blood 
pressure did not have a benefit–risk profile that 
justified this approach in persons with diabetes, 
the SPRINT investigators felt justified in testing 
the same hypothesis in patients with elevated 
blood pressure who were not known to have 
diabetes. On the heels of the ACCORD trial, the 
early termination of the SPRINT trial for reasons 
of efficacy came as a surprise. The data showed 
that more intensive lowering of blood pressure, 
below the currently recommended level, signifi-
cantly reduced rates of cardiovascular end points 
and the risk of death.26 Once scrutinized, it seems 
likely that this new information will once again 
change current authoritative recommendations for 
standard practice in an effort to improve public 
health (Fig. 1).34
Lessons Le a r ned
The privilege of conducting human research 
requires investigators to minimize the risks to 
participants and to inform participants of these 
risks by providing them with the most accurate 
current information available. Randomized trials 
should be conducted within an ethical frame-
work that allows all participants access to the 
best possible care (as determined regionally) and 
to an experimental comparator about which the 
preliminary information is sufficient to suggest 
a degree of efficacy that justifies the conduct of a 
clinical trial (given the inherent uncertainty in-
volved). As new information is generated and the 
degree of uncertainty diminished, these develop-
ments should be reflected in the selection of 
proper comparators. The history of randomized, 
controlled trials involving hypertension shows 
that the level of uncertainty or, conversely, the 
interpretation of the robustness of the currently 
available data can vary among physicians within 
a country and across geographic regions. A re-
view of this history underscores the sanctity of 
the central tenet of the consent process: prop-
erly informing the voluntary participants of rel-
evant information at the time of enrollment so 
that they can make a truly informed decision.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
References
1. Grady C. Enduring and emerging chal-
lenges of informed consent. N Engl J Med 
2015; 372: 855-62.
2. Califf RM, DeMets DL. Principles from 
clinical trials relevant to clinical practice. 
Circulation 2002; 106: 1015-21.
3. Chalmers TC, Celano P, Sacks HS, 
Smith H Jr. Bias in treatment assignment 
in controlled clinical trials. N Engl J Med 
1983; 309: 1358-61.
4. Eisenstein EL, Lemons PW II, Tardiff 
BE, Schulman KA, Jolly MK, Califf RM. 
Reducing the costs of phase III cardiovas-
cular clinical trials. Am Heart J 2005; 149: 
482-8.
5. Ridker PM, Torres J. Reported out-
comes in major cardiovascular clinical 
trials funded by for-profit and not-for-
profit organizations: 2000-2005. JAMA 
2006; 295: 2270-4.
6. Gordon D, Taddei-Peters W, Mascette 
A, Antman M, Kaufmann PG, Lauer MS. 
Publication of trials funded by the Nation-
al Heart, Lung, and Blood Institute. N Engl 
J Med 2013; 369: 1926-34.
7. Fleming TR, DeMets DL. Surrogate 
end points in clinical trials: are we being 
misled? Ann Intern Med 1996; 125: 605-13.
8. Echt DS, Liebson PR, Mitchell LB, et al. 
Mortality and morbidity in patients re-
ceiving encainide, flecainide, or placebo: 
the Cardiac Arrhythmia Suppression Trial. 
N Engl J Med 1991; 324: 781-8.
9. Kannel WB, Dawber TR, Kagan A, 
Revotskie N, Stokes J III. Factors of risk in 
the development of coronary heart dis-
ease — six year follow-up experience: the 
Framingham Study. Ann Intern Med 1961; 
55: 33-50.
10. Multiple Risk Factor Intervention Trial 
Research Group. Multiple Risk Factor In-
tervention Trial: risk factor changes and 
mortality results. JAMA 1982; 248: 1465-77.
11. Veterans Administration Cooperative 
Study Group on Antihypertensive Agents. 
Effects of treatment on morbidity in hyper-
tension: results in patients with diastolic 
blood pressures averaging 115 through 
129 mm Hg. JAMA 1967; 202: 1028-34.
12. Veterans Administration Cooperative 
Study Group on Antihypertensive Agents. 
Effects of treatment on morbidity in hyper-
tension. II. Results in patients with dia-
stolic blood pressure averaging 90 through 
114 mm Hg. JAMA 1970; 213: 1143-52.
13. Jones DW, Hall JE. The National High 
Blood Pressure Education Program: thirty 
years and counting. Hypertension 2002; 
39: 941-2.
14. Hypertension Detection and Follow-
up Program Cooperative Group. Five-year 
findings of the hypertension detection and 
follow-up program. I. Reduction in mor-
tality of persons with high blood pres-
sure, including mild hypertension. JAMA 
1979; 242: 2562-71.
15. The Australian Therapeutic Trial in 
mild hypertension: report by the Manage-
ment Committee. Lancet 1980; 1: 1261-7.
16. Amery A, Birkenhäger W, Brixko P, et 
al. Mortality and morbidity results from 
the European Working Party on High 
Blood Pressure in the Elderly trial. Lancet 
1985; 1: 1349-54.
17. Medical Research Council Working 
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on January 27, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 375;18 nejm.org November 3, 20161766
Clinical Trials Series
Party. MRC trial of treatment of mild hyper-
tension: principal results. Br Med J (Clin 
Res Ed) 1985; 291: 97-104.
18. SHEP Cooperative Research Group. 
Prevention of stroke by antihypertensive 
drug treatment in older persons with iso-
lated systolic hypertension: final results 
of the Systolic Hypertension in the Elderly 
Program (SHEP). JAMA 1991; 265: 3255-64.
19. Dahlöf B, Lindholm LH, Hansson L, 
Scherstén B, Ekbom T, Wester PO. Mor-
bidity and mortality in the Swedish Trial 
in Old Patients with Hypertension (STOP-
Hypertension). Lancet 1991; 338: 1281-5.
20. Staessen JA, Fagard R, Thijs L, et al. 
Randomised double-blind comparison of 
placebo and active treatment for older pa-
tients with isolated systolic hypertension. 
Lancet 1997; 350: 757-64.
21. Hansson L, Zanchetti A, Carruthers 
SG, et al. Effects of intensive blood-pres-
sure lowering and low-dose aspirin in pa-
tients with hypertension: principal results 
of the Hypertension Optimal Treatment 
(HOT) randomised trial. Lancet 1998; 351: 
1755-62.
22. The ALLHAT Collaborative Research 
Group. Major cardiovascular events in 
hypertensive patients randomized to doxa-
zosin vs chlorthalidone: the antihyperten-
sive and lipid-lowering treatment to pre-
vent heart attack trial (ALLHAT). JAMA 
2000; 283: 1967-75.
23. The ALLHAT Officers and Coordina-
tors for the ALLHAT Collaborative Re-
search Group. Major outcomes in high-
risk hypertensive patients randomized to 
angiotensin-converting enzyme inhibitor 
or calcium channel blocker vs diuretic: 
the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial 
(ALLHAT). JAMA 2002; 288: 2981-97.
24. Beckett NS, Peters R, Fletcher AE, et al. 
Treatment of hypertension in patients 80 
years of age or older. N Engl J Med 2008; 
358: 1887-98.
25. The ACCORD Study Group. Effects of 
intensive blood-pressure control in type 2 
diabetes mellitus. N Engl J Med 2010; 362: 
1575-85.
26. The SPRINT Research Group. A ran-
domized trial of intensive versus standard 
blood-pressure control. N Engl J Med 2015; 
373: 2103-16.
27. Lonn EM, Bosch J, López-Jaramillo P, 
et al. Blood-pressure lowering in interme-
diate-risk persons without cardiovascular 
disease. N Engl J Med 2016; 374: 2009-20.
28. Chobanian AV, Bakris GL, Black HR, 
et al. The Seventh Report of the Joint Na-
tional Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High 
Blood Pressure: the JNC 7 report. JAMA 
2003; 289: 2560-72.
29. Dahlöf B, Devereux RB, Kjeldsen SE, 
et al. Cardiovascular morbidity and mor-
tality in the Losartan Intervention For 
Endpoint reduction in hypertension study 
(LIFE): a randomised trial against ateno-
lol. Lancet 2002; 359: 995-1003.
30. Julius S, Kjeldsen SE, Weber M, et al. 
Outcomes in hypertensive patients at high 
cardiovascular risk treated with regimens 
based on valsartan or amlodipine: the 
VALUE randomised trial. Lancet 2004; 
363: 2022-31.
31. Jamerson K, Weber MA, Bakris GL, et 
al. Benazepril plus amlodipine or hydro-
chlorothiazide for hypertension in high-
risk patients. N Engl J Med 2008; 359: 2417-
28.
32. Blood Pressure Lowering Treatment 
Trialists’ Collaboration. Effects of differ-
ent blood-pressure-lowering regimens on 
major cardiovascular events: results of 
prospectively-designed overviews of ran-
domised trials. Lancet 2003; 362: 1527-35.
33. The SPS3 Study Group. Blood-pressure 
targets in patients with recent lacunar 
stroke: the SPS3 randomised trial. Lancet 
2013; 382: 507-15.
34. James PA, Oparil S, Carter BL, et al. 
2014 Evidence-based guideline for the 
management of high blood pressure in 
adults: report from the panel members 
appointed to the Eighth Joint National 
Committee (JNC 8). JAMA 2014; 311: 507-
20.
Copyright © 2016 Massachusetts Medical Society.
specialties and topics at nejm.org
Specialty pages at the Journal’s website (NEJM.org) feature articles in cardiology, 
endocrinology, genetics, infectious disease, nephrology, pediatrics, and many other 
medical specialties. These pages, along with collections of articles on clinical and 
nonclinical topics, offer links to interactive and multimedia content and feature 
recently published articles as well as material from the NEJM archive (1812–1989).
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on January 27, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
